Clinical Trials Logo

Clinical Trial Summary

The study is examining the impact of a Virtual Reality Cue Exposure Therapy intervention on heroin cravings compared to Relapse Prevention Drug Education.


Clinical Trial Description

Injection Drug Use (IDU) is a chronic, relapsing condition with grave individual and public health consequences.19-21 A majority (53%) of all past-year IDUs prefer heroin, as do 39% of single-drug injectors, second only to Methamphetamine.22,23 Non-injection heroin use (NIDU) is increasing, due to growing awareness of IDU risks, particularly HIV/AIDS;21,24-26 increased purity of street heroin;27-29 greater regulation of other opiates;30,31 and opioid abusers switching to heroin for its lower cost.32 Many NIDUs transition to IDU, incurring greater risks.2,21,33,34 Drug cravings are intense urges to use drugs35,36 and they contribute to drug use37, relapse38, and transitioning from NIDU to IDU.39 Cravings are triggered by environmental factors and due to the significance of craving in drug use and relapse they will be part of the proposed criteria for DSM5.40,41

HIV, Hepatitis C (HCV), and Sexually-Transmitted Infections (STIs) continue to be associated with both IDU and NIDU.33,42-44 Hispanics are over-represented among both IDU and NIDU heroin users.21,23,45,46 Mexican American IDUs have very low rates of HIV.10,47 However, their HCV rates are very high and continue to increase, further compromising their health.10,48,49 They also have elevated rates of high-risk sex behaviors 33,50 and they are less likely to decrease these high-risk sex behaviors than they are to decrease their injection- behavior risks, especially as they age.10,51 Furthermore, HIV/HCV/STI prevention interventions can lead to fatigue52-54 so they must continue to be delivered to at-risk populations across all relevant settings. Young Texans ages 15-24 are becoming HIV infected at high rates, with Hispanics disproportionately impacted and diagnosed later: 42% of infected Texan Hispanics receive an HIV-positive and an AIDS diagnosis within the same year, compared to 32% of Anglos and 31% of Blacks.55 Thus, early detection of high-risk Hispanics is vital, making this proposal timely and critical.

Greatly needed are novel interventions that address drug cravings (DCs), take into account environmental context, and incorporate HIV/HCV prevention components. Developing these interventions and adapting them to the many diverse at-risk populations, however, can be costly and challenging. Cue exposure therapy (CET)56,57 may be a viable approach. CET is a promising intervention that can decrease DCs by repeatedly exposing an individual to a craving inducing stimulus (e.g., a shooting gallery scenario) while simultaneously preventing the conditioned behavioral response (e.g., drug use). The individual can be trained in vitro (in the lab) to use coping skills in direct response to activated cravings, then use these skills in vivo (in the natural environment). A challenge associated with CET, for both ethical and logistical reasons, is the ability to expose individuals to realistic simulated cues of the natural environment in a secure laboratory or therapeutic setting. Virtual Reality (VR) is an innovative, cutting-edge tool that can enable researchers to overcome these obstacles. VR scenarios integrate elements from the individual's various contexts—culture, neighborhood, family, networks, and individual characteristics—into the clinical or lab setting, and provide complex multi-sensory cues through an immersive human-computer interaction.58

The public health significance of this primary project is high. Drug use in general and injection drug use (IDU) in particular are serious public health concerns, as are the rates of HCV and STIs in IDUs. Interventions that decrease craving, increase coping skills, and incorporate HIV/HCV/STI prevention components can be critical tools in treating drug use disorders and their serious health consequences. In addition, it is critical to train diverse researchers who possess intimate knowledge of the populations impacted by drug use and who understand the cultural and contextual elements of those populations, to conduct this innovative research.

The specific research hypotheses and objectives are as follows:

1. Refine and develop a Virtual Reality Heroin Scenario (VRHS) using qualitative data (i.e., photos and descriptions of heroin using sites and contexts) from our current UHDARDP's Primary Project.

2. Measure the effects of exposure to virtual reality heroin cues on craving and physiological reactivity.

Hypothesis 1a: VR cues will increase subjective heroin craving and physiological reactivity.

Hypothesis 1b: Heroin craving and physiological reactivity will decrease as a result of repeated exposure to virtual cues.

3. Compare Virtual Reality-Based Cue Exposure Therapy (VRCET) and Relapse Prevention Drug Education (RPDE) on extinction of heroin craving and physiological reactivity across cue trials.

Hypothesis 2: VRCET will attenuate cue-elicited subjective heroin craving and physiological reactivity relative to RPDE.

4. Examine the in vivo effects of VRCET on heroin craving, craving coping skills, and actual heroin use, compared to RPDE.

Hypothesis 3: VRCET will lead to a decrease in heroin craving, an increase in craving coping skills use, and decreased heroin use, in the natural environment, compared to RPDE.

5. Deliver an HIV/HCV prevention intervention to this high-risk population. Hypothesis 4: The prevention intervention will increase prevention knowledge and intention to use the skills learned.

6. Determine if medication assisted therapies, such as methadone or buprenorphine, have an impact on cue reactivity for former heroin IDU when immersed in the virtual environments, as compared to current users.

Hypothesis 5: Participants on medication assisted therapies will exhibit lower levels of cue reactivity within the VR environment than participants who are currently still using heroin. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03557632
Study type Interventional
Source University of Houston
Contact Luis R Torres, PhD
Phone 713-743-8512
Email LRTorres@uh.edu
Status Recruiting
Phase N/A
Start date August 1, 2014
Completion date March 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT00577408 - Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Phase 3
Completed NCT00218309 - Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals Phase 2
Completed NCT00000211 - Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 Phase 2
Completed NCT00000210 - Treatment Efficacy for Drug Abuse and AIDS Prevention - 1 Phase 2
Completed NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment Phase 4
Withdrawn NCT00000330 - Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 Phase 2
Completed NCT00249457 - Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2 N/A
Completed NCT00218127 - Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens Phase 2
Completed NCT04133974 - Methadone Induced Memory Retrieval-extinction Procedure in Heroin Addicts N/A
Completed NCT00015288 - Buprenorphine and Naloxone Combination Study - 10 Phase 1
Terminated NCT03711318 - Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals Phase 3
Recruiting NCT02541526 - Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia Phase 3
Active, not recruiting NCT02541513 - An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Phase 3
Completed NCT01760473 - Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone Phase 3
Terminated NCT01395797 - Pioglitazone for Heroin and for Nicotine Dependence Phase 1/Phase 2
Completed NCT01668706 - Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts N/A
Active, not recruiting NCT00609089 - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Phase 1/Phase 2
Completed NCT00684840 - Effects of Stress and Other Factors on Opiate Drug Choice. N/A
Completed NCT00759005 - Effect of Stress on Heroin-Related Memory Retrieval N/A
Completed NCT00218530 - Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1 Phase 1